Physician profile
Stuart B Carter
NPI 1477997682
$3,739.18
in general payments reported to CMS, 2019-2025
23 companies · $609 in 2025
The $609 reported for 2025 was more than what a typical Cornea and External Diseases Specialist provider received nationally (typical 2025 total: $477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $806 · 2020: $191 · 2021: $684 · 2022: $501 · 2023: $593 · 2024: $356 · 2025: $609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,557.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $1,124.87 | 2019-2021 | |
| Abbvie INC. | $828.41 | 2022-2025 | Lumigan, Durysta, Vuity |
| Alcon Vision LLC | $611.65 | 2021-2025 | Clareon, Hydrus Microstent |
| Sun Pharmaceutical Industries INC. | $207.44 | 2019-2025 | Cequa |
| Dompe US, INC. | $148.28 | 2024-2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $140.09 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $124.74 | 2025 | Xdemvy |
| Glaukos Corporation | $80.46 | 2022 | |
| Kala Pharmaceuticals, INC. | $71.74 | 2021 | |
| Shire North American Group INC | $61.13 | 2019 | |
| New World Medical,INC. | $59.68 | 2023-2024 | Clearpath, Ahmed Glaucoma Valve, Streamline |
| Ocular Therapeutix, INC. | $53.68 | 2022-2023 | Dextenza |
| Oyster Point Pharma, INC. | $32.01 | 2024 | Tyrvaya |
| Rayner Intraocular Lenses Limited | $31.45 | 2023 | Rayone Aspheric, Rayone Emv, Omidria |
| Harrow Eye, LLC | $21.51 | 2025 | Vevye |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $21.46 | 2021 | |
| Bausch & Lomb Americas INC. | $21.31 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.85 | 2022 | |
| Omeros Corporation | $17.91 | 2021 | |
| Sight Sciences, INC. | $17.85 | 2024 | Omni Surgical System |
| Spark Therapeutics, INC. | $17.49 | 2020 | |
| Eyepoint US, INC. | $13.44 | 2019 | |
| Eyevance Pharmaceuticals LLC | $12.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.